

## Review Article

# Cognitive Dysfunction after Heart Disease: A Manifestation of the Heart-Brain Axis

Chengyang Xu <sup>1,2</sup>, Xueshu Tao <sup>3</sup>, Xiaonan Ma <sup>1,2</sup>, Rui Zhao <sup>1,2</sup> and Zhipeng Cao <sup>1,2</sup>

<sup>1</sup>Department of Forensic Pathology, School of Forensic Medicine, China Medical University, No. 77, Puhe Road, Shenyang North New Area, Shenyang 110122, China

<sup>2</sup>Department of Forensic Pathophysiology, School of Forensic Medicine, China Medical University, No. 77, Puhe Road, Shenyang North New Area, Shenyang 110122, China

<sup>3</sup>Department of Pain Medicine, The First Hospital of China Medical University, Shenyang, China. No. 155 Nanjing North Street, Heping District, Shenyang, 110001, China

Correspondence should be addressed to Rui Zhao; [rzhao@cmu.edu.cn](mailto:rzhao@cmu.edu.cn) and Zhipeng Cao; [zpcao@cmu.edu.cn](mailto:zpcao@cmu.edu.cn)

Received 29 April 2021; Accepted 31 July 2021; Published 18 August 2021

Academic Editor: Ryuichi Morishita

Copyright © 2021 Chengyang Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The functions of the brain and heart, which are the two main supporting organs of human life, are closely linked. Numerous studies have expounded the mechanisms of the brain-heart axis and its related clinical applications. However, the effect of heart disease on brain function, defined as the heart-brain axis, is less studied even though cognitive dysfunction after heart disease is one of its most frequently reported manifestations. Hypoperfusion caused by heart failure appears to be an important risk factor for cognitive decline. Blood perfusion, the immune response, and oxidative stress are the possible main mechanisms of cognitive dysfunction, indicating that the blood-brain barrier, glial cells, and amyloid- $\beta$  may play active roles in these mechanisms. Clinicians should pay more attention to the cognitive function of patients with heart disease, especially those with heart failure. In addition, further research elucidating the associated mechanisms would help discover new therapeutic targets to intervene in the process of cognitive dysfunction after heart disease. This review discusses cognitive dysfunction in relation to heart disease and its potential mechanisms.

## 1. Introduction

The structure and the function of the heart and brain have been studied for several decades due to their important roles in life. With further understanding of the independent mechanisms of the two organs, scientists began to seek a connection between the heart and the brain, which was announced by Barrow in the middle of the 19th century ([1]).

The occurrence of brain disease, including cerebrovascular diseases, degenerative diseases of the nervous system, and infectious diseases of the central nervous system, can lead to myocardial injury and even cardiac dysfunction, which is described as the brain-heart axis [2–4]. On the other hand, the physiological activities and processes of the brain, such as cognitive ability and language capabilities, are directly affected by cardiac function, which is described as the heart-brain axis [5–8]. Cardiac dysfunction due to various causes,

not only existing brain disease, can lead to new brain injury [8]. In this context, an increasing number of studies have focused on the connection between the heart and the brain.

Surprisingly, few studies have explored the effects of heart disease on brain function, one of the manifestations of the heart-brain axis [9]. Herein, cognitive dysfunction and its potential mechanisms are discussed.

## 2. Cognitive Dysfunction after Heart Disease

In 1982, the term “cardiogenic dementia” was quoted in an editorial of *The Lancet*, and it is characterized as patients suffering from cognitive decline after heart disease [10]. Up to 50% of patients with heart failure (HF) reportedly develop a certain degree of cognitive impairment, with 10% of patients suffering from more severe symptoms [11–13]. In contrast, only 26% of patients with treated chronic heart

failure (CHF) develop vascular cognitive impairment [14]. The number of people grappling with heart disease has increased along with the aging population. Indeed, the incidence of HF increases with advancing age and is the most common cause of hospitalization in the United States, especially among people over 64 years old [15, 16]. Due to the lower cognitive reserve of the elderly, this population is more likely to develop cognitive dysfunction after heart disease [17].

As the main cause of HF, the high morbidity of coronary artery disease has led to the widespread implementation of coronary artery bypass grafting (CABG). In the United States alone, approximately 300,000 people undergo CABG each year [18]. In general, CABG surgery is safe in most cases; the complications mainly include postcardiac surgery syndrome, hypotensive brain injury, embolic stroke, visual defects, epilepsy, residual movement disorders, and rare peripheral nerve damage [19]. Most patients (80-90%) undergoing CABG surgery reportedly experience cognitive dysfunction at discharge [20]. Routine clinical examination found that the degree of cognitive impairment, measured by the Canadian Stroke Scale, Syndrom Kurztest, and psychiatric assessment, was often not obvious because it mainly manifested in the subcortex, involving executive dysfunction, depression, and anxiety. Over time, 42% of patients reportedly developed long-term (5 years) cognitive deficits [19]. Biomarkers of myocardial injury and cardiac dysfunction, such as cardiac troponin T (cTnT) and pro-N-terminal B-type natriuretic peptide (NT-proBNP), have been associated with lower cognitive ability among the elderly (over 60 years old), even in the absence of clinical disease [21–26]. This further illustrates that cardiac and cognitive functions are closely related.

The most obvious clinical manifestation of Alzheimer's disease (AD), a severe degenerative disease of the nervous system, is impaired cognitive function [27, 28]. Compared with a decreased total brain parenchymal volume of 0.32% per year in healthy aging individuals and brain parenchymal loss of 2% per year in AD patients, the annual loss of brain parenchymal volume was approximately 1% in patients with both high NT-proBNP levels and high carotid intima media thickness caused by reduced blood supply to the brain [29, 30]. In fact, biomarkers of myocardial injury and cardiac dysfunction have been repeatedly associated with changes in the brain structures of the elderly and the young, but only the elderly exhibit poor cognitive abilities [31]. This may be due to the higher cognitive reserve of young individuals, which can prevent the harmful effects of clinical heart disease on cognitive ability [17]. In view of these findings, it is hypothesized that the heart-brain axis runs through the processes of life [31].

### 3. Potential Mechanisms of Cognitive Dysfunction after Heart Disease

Many research groups have explored the potential mechanisms of cognitive impairment based on the important functions of the heart and brain and their interconnectivity.

Among them, blood perfusion and inflammation are the two main mechanisms that have been explored (Figure 1).

**3.1. Blood Perfusion.** The brain is a highly energy-consuming organ, accounting for approximately 20% and 25% of the body's oxygen and glucose, respectively [32]. Its function depends on a sufficient supply of oxygen and energy via the bloodstream [33]. With fluctuations in blood flow and blood pressure throughout the body, multiple systems, including the cerebrovascular self-regulation mechanism, work together to maintain the cerebral blood flow within a stable range [34]. The heart is where cerebral perfusion pressure is generated, and intra- and extracranial blood vessels change cerebral perfusion, as they deliver blood to the brain [35]. The brain receives approximately 15% of the cardiac output [36].

Hypoperfusion due to low cardiac output is a key factor in cardiovascular disease, which accelerates changes in the brain structure [37, 38]. In the case of long-term systemic hypoperfusion, the blood flow regulation mechanism may not be able to compensate to protect the brain, resulting in insufficient cerebral perfusion, which is associated with impaired brain function [32]. Decreased cerebral blood flow in patients with HF has been associated with increased prevalence of cognitive dysfunction, and even a subclinical decrease in cardiac output has been associated with impaired cognitive function [39–41]. Patients with CHF are more prone to brain parenchymal loss, especially gray matter, due to low cerebral blood flow [42–44]. This is because the higher metabolic demand of gray matter requires more than two-thirds of the cerebral blood flow [32, 36]. Reduced gray matter volume was reportedly associated with impairment of various cortical areas involved in executive cognitive function [45]. Furthermore, surgery to improve cardiac function, such as heart transplantation or resynchronization, has been shown to help develop cognitive function [46, 47]. Therefore, cardiac dysfunction can lead to hypoperfusion and ultimately cause cognitive impairment.

Vascular damage in the brain itself, such as small vessel disease, may also increase the vulnerability of the brain to changes in perfusion pressure [27]. In contrast, changes in cerebral blood flow homeostasis can promote clinical or subclinical brain injury by aggravating microvascular damage. For example, fluctuations in cerebral perfusion can lead to changes in microvascular structure, expression of vascular cell receptors, microvascular permeability, and vascular remodeling [48, 49].

Increasing evidence supports the role of blood perfusion in the pathogenesis of AD [27, 28]. Early AD without symptoms manifests as cognitive decline caused by hypoperfusion, and increasing cerebral blood flow has been shown to improve AD symptoms [28]. This also supports the close connection between blood perfusion and cognitive decline.

In the case of cerebral hypoperfusion, the metabolic activity of the whole brain is significantly reduced [50]. Specifically, the metabolic level of the parietal area in patients with HF was reportedly reduced compared with that in healthy volunteers [51, 52]. However, in HF patients with hibernating myocardium and impaired global left ventricular




FIGURE 1: Potential mechanisms of cognitive dysfunction after heart diseases.

function, the metabolism of the frontal lobe area was compensatorily increased, while glucose metabolism of the hippocampus and parahippocampus, which are vulnerable to dementia, was decreased, leading to memory loss [50, 53]. These differential changes in metabolic activity were related to self-regulation efficiency in different areas [54]. As part of the neocortex, the frontal lobe may have higher self-regulation efficiency and sensitivity than the original cortex, including the hippocampus and parahippocampus [55]. Therefore, when cerebral blood flow begins to decrease, the forehead area may be compensated first to maintain a certain degree of energy metabolism.

Except for heart diseases, such as myocarditis and myocardial infarction (MI) that directly lead to inflammation, hypoperfusion can cause inflammation of brain tissues in diseases with decreased cardiac function, such as HF [56]. In response to hypoperfusion injury or interruption of perfusion, cell respiration is quickly exhausted, and adenosine triphosphate (ATP) is consumed and regenerated without compensation. Subsequently, reactive oxygen species (ROS) are produced [57, 58]. Specific inflammatory changes are discussed in the next section.

Aerobic exercise has demonstrated amelioratory effects on the blood supply to the brain. On the basis of the mechanism discussed above, aerobic exercise is beneficial for cardiac disease patients with cognitive impairment. Regular aerobic physical activity can increase the blood flow in the prefrontal cortex, promote the formation of blood vessels in the frontal cortex, and increase the concentration of the vascular endothelial growth factor [59]. Moreover, long-term continuous aerobic exercise can promote cardiovascular health by increasing vagal tone and reducing sinus node sympathetic nerve activity [60]. Tanne et al. reported that HF patients with the New York Heart Association (NYHA) functional class III status and an ejection fraction of 35% demonstrated improved selective attention and mental exercise speed after long-term aerobic exercise [15].

**3.2. Inflammatory Response and Oxidative Stress.** The inflammatory response and oxidative stress are usually interdependent and may be potentially associated with brain dysfunction after heart disease [61, 62]. Studies have reported

that inflammation occurs in the brain after MI. However, local inflammation of the skeletal muscle has no effect on the heart and brain, indicating that the connection between the heart and the brain is closer than that of other organs when the heart is injured [63]. On the one hand, several heart diseases, such as myocarditis and MI, will directly cause inflammation; on the other hand, hypoperfusion caused by diseases with decreased heart function will also lead to brain inflammation [56]. In addition, decreased cardiac function can change inflammatory marker levels in the brain [64]. The expression of inflammatory genes, such as toll-like receptor- (TLR-) 4, tumor necrosis factor- (TNF-)  $\alpha$ , and interleukin- (IL-) 6, was significantly upregulated in the cortex and hippocampus in a mouse model of HF [65]. As for the pathological mechanism of HF, the landmark event in its early stage is the appearance of a large number of proinflammatory factors in the heart and peripheral circulation, such as TNF- $\alpha$ , IL-1, IL-6, IL-8, and monocyte chemoattractant protein- (MCP-) 1, mainly derived from neutrophils, monocytes, and macrophages [66]. These proinflammatory factors reach the brain via the bloodstream, causing inflammation in the brain.

TNF- $\alpha$ , which is considered the main regulator of the brain's proinflammatory response, can cause cell damage and death by increasing neurotoxicity via neuronal glutamate [67, 68]. Recent studies have shown that the ASK1-p38-TNF- $\alpha$  pathway is involved in the destruction of tight junctions soon after chronic cerebral hypoperfusion [69]. Insufficient cerebral perfusion affects the level of IL-1 $\beta$  in the central nervous system, which is an important regulator of the inflammatory cascade [70]. TNF- $\alpha$  and IL-1 $\beta$  in the ischemic brain can reportedly induce the production of IL-6, and increased IL-6 levels in the serum and cerebrospinal fluid are related to cognitive impairment [71]. Furthermore, the presence of IL-1 $\beta$  and TNF- $\alpha$  can upregulate the expression and function of CD73, which plays a protective role in the occurrence of white matter lesions induced by cerebral hypoperfusion and cognitive impairment by regulating the activation of glial cells and expression of proinflammatory cytokines [72]. Specifically, upregulation of CD73 expression and activity in the corpus callosum after chronic hypoperfusion mediates the production of adenosine, which can inhibit

the release of inflammatory cytokines IL-1 $\beta$ , IL-6, and TNF- $\alpha$ . Therefore, CD73 plays a key role in the counter-regulatory feedback mechanism, helping to relieve inflammation [69].

The inflammatory response and oxidative stress mainly cause cognitive dysfunction through damage to the self-repair mechanism, destruction of the blood-brain barrier (BBB), and activation of glial cells [61, 73, 74]. Among them, the damaged BBB and activated glial cells will also affect each other, leading to deposition of amyloid- $\beta$  (A $\beta$ ) and causing damage to the cognitive function of the brain [75–77].

In view of the importance of the inflammatory response and oxidative stress, anti-inflammatory or antioxidant therapies have become an innovative clinical approach [78]. Naturally, the optimal drug should simultaneously treat heart disease and cognitive dysfunction, and angiotensin-converting enzyme inhibitors (ACEIs) have received the most attention. Among them, enalapril inhibits the proinflammatory activity of angiotensin II [79, 80]. Continuous treatment with enalapril has been shown to reduce acute and chronic inflammation in the heart and brain [63]. Animal experiments suggested that the effectiveness of ACEIs on neuroinflammation after MI was based on acute application, since late application missed the acute anti-inflammation stage and was not beneficial for alleviating chronic neuroinflammation [81]. As for other noncardiac treatment drugs, translocator protein inhibitors, such as 4'-chloridiazepam, are believed to modulate neuroinflammation and exert cardioprotective effects during ischemia-reperfusion injury through antioxidant mechanisms [82]. Nonsteroidal anti-inflammatory drugs have also demonstrated a certain effectiveness against amyloid deposition [83].

**3.2.1. Damaged Repair Mechanism and Development of Small Vessel Disease.** The inflammatory response and oxidative stress are believed to play important roles in neurovascular dysfunction. Oxidative stress can cause endothelial dysfunction, BBB disruption, and cytokine production [61]. In turn, inflammation can enhance oxidative stress by upregulating the expression of enzymes that produce ROS and downregulating antioxidant defense capabilities [62]. Further, the inflammatory response and oxidative stress disrupt the repair mechanism of damaged white matter by interfering with the proliferation, migration, and differentiation of oligodendrocyte progenitor cells [73, 84]. The loss of growth factors, which are produced by the brain, reportedly occurs in vascular cognitive impairment, further damaging the repair mechanism and aggravating cognitive impairment [74].

Apolipoprotein E (ApoE) subsequently affects neurovascular units through pericytes, causing changes in microvascular flow and triggering neurodegenerative changes [85]. Cerebral arterioles are particularly vulnerable to these changes, promoting the development of small vessel diseases, such as cerebral amyloid angiopathy and arteriole sclerosis [9]. Small vessel diseases lead to weakened cerebral vasoconstriction, which in turn promotes cerebral blood pressure changes [86, 87]. Combined, these factors eventually lead to cognitive impairment, stroke symptoms, and changes in brain structure, such as white matter lesions, lacunar infarction, and substantial bleeding [9].

Overall, the inflammatory response and hypoperfusion can damage the brain repair mechanism, which in turn promote the occurrence of small vessel diseases.

**3.2.2. Destruction of the Blood-Brain Barrier.** Abnormal function of the BBB, including activated endothelial cells, destroyed pericytes, and abnormal endothelial-endothelial and endothelial-pericyte connections, occupies an important position in the pathogenesis of cognitive dysfunction after heart disease [35]. Inflammation and ROS are thought to be involved in these changes, since the generation of ROS destroys the ion gradient [88]. Endothelial cells, the main component of the BBB, have been shown to be damaged by an increase in intracellular calcium ion levels [89]. In addition, pericytes are reportedly involved in regulating BBB function and are highly likely to cause destructive inflammation [85, 90]. The breakdown of the BBB is caused by activation of the proinflammatory pathway of pericytes, involving cyclophilin A-nuclear factor- $\kappa$ B-matrix-metalloproteinase-9 [69, 74]. Cerebral endothelial tight junction proteins, such as claudin-5, play a key role in maintaining the BBB [91]. Thus, decreased levels of claudin-5 in the corpus callosum destroy the BBB via the ASK1-p38-TNF- $\alpha$  pathway. Animal experiments have demonstrated that the use of compound K811, a specific ASK1 inhibitor, can prevent cognitive impairment in a mouse model of hypoperfusion [72]. ASK1 may be a new target molecule for the treatment of cognitive dysfunction caused by cerebral hypoperfusion.

Damage to the BBB increases its permeability, causing leakage of plasma components and exchange of substances [92]. After the occurrence of hypoperfusion, immunoglobulin (Ig) G leakage from the corpus callosum indicated BBB rupture [93]. This leakage occurred when glial cells, including astrocytes and microglia, were not observed to be activated [94]. Moreover, the level of proinflammatory markers was related to the degree of BBB rupture [95]. Notably, the complete BBB plays an important role in preventing extravasation of toxic factors from circulating to the brain parenchyma. For instance, peripheral blood-derived substances, such as thrombin, can aggravate central nervous system inflammation [96, 97]. BBB dysfunction thus further exacerbates microvascular damage, promotes secondary inflammation, and damages blood vessel tension, leading to luminal stenosis and tissue ischemia [98].

Generally, destruction of the BBB by ROS and inflammation after heart disease will lead to further aggravation of inflammation and promote contact of neurotoxic proteins with neurons. The relationship between BBB destruction and immune cell activation is described later.

**3.2.3. Activation of Glial Cells.** After inflammation occurs, astrocytes are activated slightly earlier than microglia [63]. The activation of astrocytes after MI is directly related to the inflammation induced by infarction, and may be caused by proinflammatory cytokines [75].  $^{11}$ C-methionine uptake can help reflect inflammation in the brain [99]. Neutrophils and proinflammatory monocytes display higher rates of methionine uptake, which affects the activation of astrocytes



[100]. In addition, active astrocytes may be neurotoxic and produce specific inflammatory cytokines and ROS [75].

The increased permeability of the BBB also enhances the adhesion and migration of monocytes from the periphery to the central nervous system, and then differentiation into microglia to promote neuroinflammation [76]. As the main agonist of neuroinflammation, the production of microglia is the central nervous system's immune response to local injury or systemic activation [101]. Neuroinflammation is considered key to the progression of AD [102], in which microglia are activated by amyloid deposition and exert neurotoxic effects, thereby further aggravating inflammation and expanding amyloid deposition [77]. Subsequently, the activated microglia produce a large amount of proinflammatory cytokines, leading to cumulative damage to the tissue [103]. Miyanohara et al. reported that proinflammatory cytokines (such as IL6 and TNF- $\alpha$ ) and obvious tissue damage were significantly detected in the white matter of a mouse model of chronic cerebral hypoperfusion with BCAS [104]. Proinflammatory cytokines also play an important role in oligodendrocyte toxicity [105]. This relationship is maturation-dependent, i.e., proinflammatory cytokines are more toxic to immature oligodendrocytes than mature oligodendrocytes [106].

To study the mechanism of inflammation in depth, Miyanohara et al. confirmed that transient receptor potential melastatin 2 (TRPM2), a Ca<sup>2+</sup> permeable channel, participated in cognitive impairment related to chronic cerebral hypoperfusion by enhancing the production of cytokines, leading to subsequent white matter damage [104, 107]. Specifically, TRPM2, expressed in microglia/macrophages, mediated the upregulation of proinflammatory cytokines in white matter [104]. In the regulation of TRPM2, ROS was considered an endogenous agonist of TRPM2, and high concentrations of hydrogen peroxide induced TRPM2-mediated neuronal death [108–110].

Apart from TRPM2, IL1R, CX3CR1, leptin, and tamoxifen may also be involved in regulation of the inflammatory response. Zhou et al. reported that the loss of IL1R expression improved white matter damage and promoted the migration of oligodendrocyte precursor cells from the subventricular zone [111]. Further, CX3CR1 silencing in microglia reduced cytokine release, white matter damage, and cognitive impairment [112]. Leptin reportedly increased the expression of proinflammatory cytokines induced by hypoxia in BV2 microglia [113]. Du et al. reported that leptin receptor deletion protected mice from cognitive dysfunction induced by cerebral hypoperfusion and white matter damage by inhibiting glial cell activation and the proinflammatory response, which promoted the expression of anti-inflammatory cytokines in white matter and activation of M2 microglia [114]. Tamoxifen significantly reduced the activation and inflammatory response of microglia, facilitated the polarization of microglia to the M2 phenotype, enhanced the proliferation and differentiation of oligodendrocyte precursor cells, and reduced the expression of TNF- $\alpha$  and IL-1 $\beta$  [115].

In short, inflammation and destruction of BBB permeability after heart disease promote the activation of glial cells, leading to neuroinflammation, which is considered an important factor in the progression of AD.

**3.2.4. Amyloid- $\beta$  Deposition.** Although HF and cognitive dysfunction in patients with AD have long been considered independent factors, an increasing number of studies have confirmed that they may be related, with similarities such as common risk factors and similar epidemiological stratification [88]. Moreover, AD-related neuropathology was reported in a rat model after acute blood perfusion ceased, including A $\beta$  deposition in the hippocampus, endothelium, and neocerebral cortex, which led to neuronal death [116].

Under normal circumstances, A $\beta$  is removed from the brain through the BBB, the interstitial bulk flow clearance (glymphatic) system, or meningeal lymphatic vessels [117, 118]. Under chronic hypoperfusion, these drainage systems are damaged, and A $\beta$  accumulates in the perivascular space [119]. In the process of A $\beta$  deposition, new evidence suggests that immune mediators also contribute to disease progression, especially in microglia [76]. Such scavenger cells play a role in both the inflammatory cascade and A $\beta$  clearance in the brain [120]. Chronic low blood flow and glucose transport conditions result in only a few activated microglia in the area around the A $\beta$  plaque, accompanied by impaired function [76]. Thus, the ability of microglia to eliminate A $\beta$  is further reduced, providing an ideal environment for accumulation, aggregation, and further formation of plaques. In addition, active astrocytes also express high levels of amyloid precursor protein [121]. Therefore, astrocyte activation induced by heart disease may lead to a vicious cycle of amyloid production and further neuroinflammation [122].

Studies with mouse models of AD and AD patients reported that A $\beta$ , in turn, caused oxidative imbalance through A $\beta$  accumulation in the mitochondria, which aggravated mitochondrial dysfunction, ROS production, and overall oxidative imbalance [123, 124]. The cycle was further exacerbated by the inflammatory response and oxidative stress causing vasoconstriction and promoting destruction of the BBB. A $\beta$  accumulation in the brain also reportedly has a profound effect on blood vessels, thereby promoting neurodegenerative processes [88].

In summary, under the condition of chronic hypoperfusion, damage to the drainage system and decreased ability of glial cells to clear A $\beta$  lead to the accumulation of A $\beta$ , eventually causing cognitive impairment. Interestingly, HF with preserved ejection fraction can promote cognitive dysfunction in AD and vice versa [88]. Overall, HF and cognitive dysfunction are interrelated, and their common pathogenesis may be systemic [125]. In view of the important roles of the heart and brain, the relationship between them must be taken seriously.

## 4. Future Direction

Cognitive dysfunction occurs in a large number of patients with heart disease, causing a great burden to families and the healthcare system. However, systematic research still needs to be conducted. Recently, increasing evidence has shown that extracellular vesicles are involved in molecular transport within and between organs, including interactions between the heart and brain [126]. In the brain, exosomes have important physiological functions, such as promoting

signal transmission between neurons and glial cells and participating in  $A\beta$  metabolism [127, 128]. At present, exosomes, as members of extracellular vesicles, are also known to participate in the heart-brain axis. Sun et al. described a new mechanism of brain damage originating from the heart, in which high levels of microRNA- (miR-) 1 were produced in the ischemic and marginal regions of the heart in a mouse model of MI. Transported by exosomes from the heart, miR-1 reached the hippocampus, reduced the expression of tubulin polymerization-promoting protein, and affected the stability of microtubules in neurons [129]. Furthermore, the expression of miR-133b, which is responsible for the development of midbrain dopaminergic neurons, was reportedly decreased in circulation after MI [130].

In addition to probing the mechanisms of cognitive dysfunction after heart disease, the clinical application of these mechanisms is also an important point for scientists and doctors. The impact on cognitive function of drugs used to treat heart disease needs to be carefully evaluated, especially new therapies such as sacubitril/valsartan. Theoretically, neprilysin inhibition reduces  $A\beta$  degradation in the central nervous system, thereby increasing the risk of AD [131]. ACEI drugs pose similar risks, as they are involved in the process of converting amyloid- $\beta$ 1-42 into  $A\beta$ 1-40. ACEIs block this process and increase the deposition of  $A\beta$ 1-42 in the brain [59]. However, the specific role of these drugs in the process of cognitive dysfunction remains to be further elucidated.

### Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

### Authors' Contributions

Chengyang Xu and Xueshu Tao contributed equally to this work.

### Acknowledgments

This study was financially supported by the National Natural Science Foundation of China (grant number 82002001), the Natural Science Foundation of Liaoning Province (grant number 20180530004), and the Open Project of Forensic Pathology Key Laboratory, Ministry of Public Security of China (grant number GABFYBL201804).

### References

- [1] C. Templin, J. Hänggi, C. Klein et al., "Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome," *European Heart Journal*, vol. 40, no. 15, pp. 1183–1187, 2019.
- [2] C. Xu, A. Zheng, T. He, and Z. Cao, "Brain-heart axis and biomarkers of cardiac damage and dysfunction after stroke: a systematic review and meta-analysis," *International Journal of Molecular Sciences*, vol. 21, no. 7, p. 2347, 2020.
- [3] Z. Chen, P. Venkat, D. Seyfried, M. Chopp, T. Yan, and J. Chen, "Brain-heart interaction: cardiac complications after stroke," *Circulation Research*, vol. 121, no. 4, pp. 451–468, 2017.
- [4] I. Altun, Y. Unal, O. Basaran et al., "Increased epicardial fat thickness correlates with aortic stiffness and N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke patients," *Texas Heart Institute Journal*, vol. 43, no. 3, pp. 220–226, 2016.
- [5] H. Fuhrer, M. Reinhard, and W. D. Niesen, "Paradigm change? Cardiac output better associates with cerebral perfusion than blood pressure in ischemic stroke," *Frontiers in Neurology*, vol. 8, p. 706, 2017.
- [6] A. M. Hooghiemstra, A. E. Leeuwis, A. S. Bertens et al., "Frequent cognitive impairment in patients with disorders along the heart-brain axis," *Stroke*, vol. 50, no. 12, pp. 3369–3375, 2019.
- [7] P. A. Wolf, R. D. Abbott, and W. B. Kannel, "Atrial fibrillation as an independent risk factor for stroke: the Framingham Study," *Stroke*, vol. 22, no. 8, pp. 983–988, 1991.
- [8] D. Battaglini, C. Robba, A. Lopes da Silva et al., "Brain-heart interaction after acute ischemic stroke," *Critical Care*, vol. 24, no. 1, p. 163, 2020.
- [9] M. A. van Buchem, G. J. Biessels, H. P. Brunner la Rocca et al., "The heart-brain connection: a multidisciplinary approach targeting a missing link in the pathophysiology of vascular cognitive impairment," *Journal of Alzheimer's Disease*, vol. 42, Suppl 4, pp. S443–S451, 2014.
- [10] S. T. McCarthy, L. Wollner, G. A. Rosenberg, and K. Y. Haaland, "Cardiogenic dementia," *Lancet*, vol. 318, no. 8256, p. 1171, 1981.
- [11] S. J. Pressler, "Cognitive functioning and chronic heart failure," *The Journal of Cardiovascular Nursing*, vol. 23, no. 3, pp. 239–249, 2008.
- [12] R. L. Vogels, J. M. Oosterman, B. van Harten et al., "Profile of cognitive impairment in chronic heart failure," *Journal of the American Geriatrics Society*, vol. 55, no. 11, pp. 1764–1770, 2007.
- [13] M. Huijts, R. J. van Oostenbrugge, A. Duits et al., "Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial," *European Journal of Heart Failure*, vol. 15, no. 6, pp. 699–707, 2013.
- [14] G. Zuccalà, G. onder, C. Pedone et al., "Hypotension and cognitive impairment: selective association in patients with heart failure," *Neurology*, vol. 57, no. 11, pp. 1986–1992, 2001.
- [15] D. Tanne, D. Freimark, A. Poreh et al., "Cognitive functions in severe congestive heart failure before and after an exercise training program," *International Journal of Cardiology*, vol. 103, no. 2, pp. 145–149, 2005.
- [16] L. H. Curtis, D. J. Whellan, B. G. Hammill et al., "Incidence and prevalence of heart failure in elderly persons, 1994–2003," *Archives of Internal Medicine*, vol. 168, no. 4, pp. 418–424, 2008.
- [17] Y. Stern, "Cognitive reserve in ageing and Alzheimer's disease," *Lancet Neurology*, vol. 11, no. 11, pp. 1006–1012, 2012.
- [18] D. B. Mark and M. F. Newman, "Protecting the brain in coronary artery bypass graft surgery," *JAMA*, vol. 287, no. 11, pp. 1448–1450, 2002.
- [19] G. C. Román, "Vascular dementia may be the most common form of dementia in the elderly," *Journal of the Neurological Sciences*, vol. 203–204, pp. 7–10, 2002.

- [20] G. W. Roach, M. Kanchuger, C. M. Mangano et al., "Adverse cerebral outcomes after coronary bypass surgery," *The New England Journal of Medicine*, vol. 335, no. 25, pp. 1857–1864, 1996.
- [21] S. S. Mirza, R. F. A. G. de Bruijn, P. J. Koudstaal et al., "The N-terminal pro-B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-year follow-up study in the general population," *Journal of Neurology, Neurosurgery, and Psychiatry*, vol. 87, no. 4, pp. 356–362, 2016.
- [22] B. Sabayan, M. A. van Buchem, A. J. M. de Craen et al., "N-terminal pro-brain natriuretic peptide and abnormal brain aging: the AGES-Reykjavik Study," *Neurology*, vol. 85, no. 9, pp. 813–820, 2015.
- [23] L. B. Daniels, G. A. Laughlin, D. Kritz-Silverstein et al., "Elevated Natriuretic Peptide Levels and Cognitive Function in Community-dwelling Older Adults," *The American Journal of Medicine*, vol. 124, no. 7, pp. 670.e1–670.e8, 2011.
- [24] K. van den Hurk, Y. D. Reijmer, E. van den Berg et al., "Heart failure and cognitive function in the general population: the Hoorn Study," *European Journal of Heart Failure*, vol. 13, no. 12, pp. 1362–1369, 2011.
- [25] P. G. van Peet, A. J. M. de Craen, J. Gussekloo, and W. de Ruijter, "Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus Study," *Age (Dordrecht, Netherlands)*, vol. 36, no. 3, p. 9660, 2014.
- [26] T. Kerola, T. Nieminen, S. Hartikainen, R. Sulkava, O. Vuolteenaho, and R. Kettunen, "B-type natriuretic peptide as a predictor of declining cognitive function and dementia—a cohort study of an elderly general population with a 5-year follow-up," *Annals of Medicine*, vol. 42, no. 3, pp. 207–215, 2010.
- [27] P. B. Gorelick, A. Scuteri, S. E. Black et al., "Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association," *Stroke*, vol. 42, no. 9, pp. 2672–2713, 2011.
- [28] J. C. de la Torre, "Chapter 3 cerebrovascular and cardiovascular pathology in Alzheimer's disease," *International Review of Neurobiology*, vol. 84, pp. 35–48, 2009.
- [29] R. I. Scahill, C. Frost, R. Jenkins, J. L. Whitwell, M. N. Rossor, and N. C. Fox, "A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging," *Archives of Neurology*, vol. 60, no. 7, pp. 989–994, 2003.
- [30] L. C. Silbert, J. F. Quinn, M. M. Moore et al., "Changes in pre-morbid brain volume predict Alzheimer's disease pathology," *Neurology*, vol. 61, no. 4, pp. 487–492, 2003.
- [31] M. G. J. Veugen, R. M. A. Henry, H. P. Brunner-la Rocca et al., "Cross-sectional associations between cardiac biomarkers, cognitive performance, and structural brain changes are modified by age," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 38, no. 8, pp. 1948–1958, 2018.
- [32] B. Sabayan, M. A. van Buchem, S. Sigurdsson et al., "Cardiac and carotid markers link with accelerated brain atrophy: the AGES-Reykjavik Study (Age, Gene/Environment Susceptibility-Reykjavik)," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 36, no. 11, pp. 2246–2251, 2016.
- [33] M. Erecińska and I. A. Silver, "Tissue oxygen tension and brain sensitivity to hypoxia," *Respiration Physiology*, vol. 128, no. 3, pp. 263–276, 2001.
- [34] D. Attwell, A. M. Buchan, S. Charpak, M. Lauritzen, B. A. MacVicar, and E. A. Newman, "Glial and neuronal control of brain blood flow," *Nature*, vol. 468, no. 7321, pp. 232–243, 2010.
- [35] K. Ritz, M. A. van Buchem, and M. J. Daemen, "The heart-brain connection: mechanistic insights and models," *Netherlands Heart Journal*, vol. 21, no. 2, pp. 55–57, 2013.
- [36] C. K. Willie and K. J. Smith, "Fuelling the exercising brain: a regulatory quagmire for lactate metabolism," *The Journal of Physiology*, vol. 589, no. 4, pp. 779–780, 2011.
- [37] B. V. Zlokovic, "Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders," *Nature Reviews. Neuroscience*, vol. 12, no. 12, pp. 723–738, 2011.
- [38] K. Kisler, A. R. Nelson, A. Montagne, and B. V. Zlokovic, "Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease," *Nature Reviews. Neuroscience*, vol. 18, no. 7, pp. 419–434, 2017.
- [39] O. B. Paulson, J. O. Jarden, J. Godtfredsen, and S. Vorstrup, "Cerebral blood flow in patients with congestive heart failure treated with captopril," *The American Journal of Medicine*, vol. 76, no. 5, pp. 91–95, 1984.
- [40] B. R. Choi, J. S. Kim, Y. J. Yang et al., "Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy," *The American Journal of Cardiology*, vol. 97, no. 9, pp. 1365–1369, 2006.
- [41] A. L. Jefferson, J. J. Himali, R. Au et al., "Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study)," *The American Journal of Cardiology*, vol. 108, no. 9, pp. 1346–1351, 2011.
- [42] M. Muller, Y. van der Graaf, A. Algra et al., "Carotid atherosclerosis and progression of brain atrophy: the SMART-MR study," *Annals of Neurology*, vol. 70, no. 2, pp. 237–244, 2011.
- [43] S. R. Seaman and I. R. White, "Review of inverse probability weighting for dealing with missing data," *Statistical Methods in Medical Research*, vol. 22, no. 3, pp. 278–295, 2013.
- [44] A. Horstmann, S. Frisch, R. T. Jentzsch, K. Muller, A. Villringer, and M. L. Schroeter, "Resuscitating the heart but losing the brain: brain atrophy in the aftermath of cardiac arrest," *Neurology*, vol. 74, no. 4, pp. 306–312, 2010.
- [45] M. Amanzio, S. Palermo, M. Stanziano et al., "Investigating neuroimaging correlates of early frailty in patients with behavioral variant frontotemporal dementia: a MRI and FDG-PET study," *Frontiers in Aging Neuroscience*, vol. 13, article 637796, 2021.
- [46] D. D. Roman, S. H. Kubo, S. Ormaza, G. S. Francis, A. J. Bank, and S. J. Shumway, "Memory improvement following cardiac transplantation," *Journal of Clinical and Experimental Neuropsychology*, vol. 19, no. 5, pp. 692–697, 1997.
- [47] R. J. Petrucci, J. G. Rogers, L. Blue et al., "Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support," *The Journal of Heart and Lung Transplantation*, vol. 31, no. 1, pp. 27–36, 2012.
- [48] G. J. del Zoppo and T. Mabuchi, "Cerebral microvessel responses to focal ischemia," *Journal of Cerebral Blood Flow and Metabolism*, vol. 23, no. 8, pp. 879–894, 2003.
- [49] T. Hayashi, K. Deguchi, S. Nagotani et al., "Cerebral ischemia and angiogenesis," *Current Neurovascular Research*, vol. 3, no. 2, pp. 119–129, 2006.



- [50] M. Yun, B. Nie, W. Wen et al., "Assessment of cerebral glucose metabolism in patients with heart failure by  $^{18}\text{F}$ -FDG PET/CT imaging," *Journal of Nuclear Cardiology*, 2020.
- [51] M. S. Kim and J. J. Kim, "Heart and brain interconnection - clinical implications of changes in brain function during heart failure," *Circulation Journal*, vol. 79, no. 5, pp. 942–947, 2015.
- [52] C. W. Lee, J. H. Lee, T. H. Lim et al., "Prognostic significance of cerebral metabolic abnormalities in patients with congestive heart failure," *Circulation*, vol. 103, no. 23, pp. 2784–2787, 2001.
- [53] C. Domingos, J. M. Pêgo, and N. C. Santos, "Effects of physical activity on brain function and structure in older adults: a systematic review," *Behavioural Brain Research*, vol. 402, article 113061, 2020.
- [54] M. A. Horsfield, J. L. Jara, N. P. Saeed, R. B. Panerai, and T. G. Robinson, "Regional differences in dynamic cerebral autoregulation in the healthy brain assessed by magnetic resonance imaging," *PLoS One*, vol. 8, no. 4, article e62588, 2013.
- [55] O. M. Henriksen, M. B. Vestergaard, U. Lindberg et al., "Interindividual and regional relationship between cerebral blood flow and glucose metabolism in the resting brain," *Journal of Applied Physiology*, vol. 125, no. 4, pp. 1080–1089, 2018.
- [56] I. Akiguchi, H. Tomimoto, T. Suenaga, H. Wakita, and H. Budka, "Alterations in glia and axons in the brains of Binswanger's disease patients," *Stroke*, vol. 28, no. 7, pp. 1423–1429, 1997.
- [57] S. Love and J. S. Miners, "Cerebral hypoperfusion and the energy deficit in Alzheimer's disease," *Brain Pathology*, vol. 26, no. 5, pp. 607–617, 2016.
- [58] X. Zhu, M. A. Smith, K. Honda et al., "Vascular oxidative stress in Alzheimer disease," *Journal of the Neurological Sciences*, vol. 257, no. 1-2, pp. 240–246, 2007.
- [59] T. O. Mene-Afejuku, M. Pernia, U. N. Ibebuogu et al., "Heart failure and cognitive impairment: clinical relevance and therapeutic considerations," *Current Cardiology Reviews*, vol. 15, no. 4, pp. 291–303, 2019.
- [60] M. L. M. Rêgo, D. A. R. Cabral, and E. B. Fontes, "Cognitive deficit in heart failure and the benefits of aerobic physical activity," *Arquivos Brasileiros de Cardiologia*, vol. 110, no. 1, pp. 91–94, 2018.
- [61] C. Marchesi, P. Paradis, and E. L. Schiffrin, "Role of the renin-angiotensin system in vascular inflammation," *Trends in Pharmacological Sciences*, vol. 29, no. 7, pp. 367–374, 2008.
- [62] R. Gill, A. Tsung, and T. Billiar, "Linking oxidative stress to inflammation: toll-like receptors," *Free Radical Biology & Medicine*, vol. 48, no. 9, pp. 1121–1132, 2010.
- [63] J. T. Thackeray, H. C. Hupe, Y. Wang et al., "Myocardial inflammation predicts remodeling and neuroinflammation after myocardial infarction," *Journal of the American College of Cardiology*, vol. 71, no. 3, pp. 263–275, 2018.
- [64] C. Toledo, D. C. Andrade, H. S. Díaz, N. C. Inestrosa, and R. del Rio, "Neurocognitive disorders in heart failure: novel pathophysiological mechanisms underpinning memory loss and learning impairment," *Molecular Neurobiology*, vol. 56, no. 12, pp. 8035–8051, 2019.
- [65] X. Hong, L. Bu, Y. Wang et al., "Increases in the risk of cognitive impairment and alterations of cerebral  $\beta$ -amyloid metabolism in mouse model of heart failure," *PLoS One*, vol. 8, no. 5, article e63829, 2013.
- [66] N. Glezeva and J. A. Baugh, "Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target," *Heart Failure Reviews*, vol. 19, no. 5, pp. 681–694, 2014.
- [67] R. T. Perry, J. S. Collins, H. Wiener, R. Acton, and R. C. Go, "The role of TNF and its receptors in Alzheimer's disease," *Neurobiology of Aging*, vol. 22, no. 6, pp. 873–883, 2001.
- [68] J. Y. Zou and F. T. Crews, "TNF $\alpha$  potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF $\kappa$ B inhibition," *Brain Research*, vol. 1034, no. 1-2, pp. 11–24, 2005.
- [69] X. Hou, X. Liang, J. F. Chen, and J. Zheng, "Ecto-5'-nucleotidase (CD73) is involved in chronic cerebral hypoperfusion-induced white matter lesions and cognitive impairment by regulating glial cell activation and pro-inflammatory cytokines," *Neuroscience*, vol. 297, pp. 118–126, 2015.
- [70] S. S. Shafiq, W. S. Griffin, and M. K. O'Banion, "The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective," *Journal of Neuroinflammation*, vol. 5, no. 1, p. 7, 2008.
- [71] C. B. Wright, R. L. Sacco, T. R. Rundek, J. B. Delman, L. R. E. Rabbani, and M. S. V. Elkind, "Interleukin-6 is associated with cognitive function: the Northern Manhattan Study," *Journal of Stroke and Cerebrovascular Diseases*, vol. 15, no. 1, pp. 34–38, 2006.
- [72] K. Toyama, N. Koibuchi, K. Uekawa et al., "Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 3, pp. 616–625, 2014.
- [73] J. E. Simpson, M. S. Fernando, L. Clark et al., "White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses," *Neuropathology and Applied Neurobiology*, vol. 33, no. 4, pp. 410–419, 2007.
- [74] G. M. Savva, S. B. Wharton, P. G. Ince, G. Forster, F. E. Matthews, and C. Brayne, "Age, neuropathology, and dementia," *The New England Journal of Medicine*, vol. 360, no. 22, pp. 2302–2309, 2009.
- [75] P. Bascuñana, A. Hess, T. Borchert et al., " $^{11}\text{C}$ -Methionine PET identifies astroglia involvement in heart-brain inflammation networking after acute myocardial infarction," *Journal of Nuclear Medicine*, vol. 61, no. 7, pp. 977–980, 2020.
- [76] F. L. Heppner, R. M. Ransohoff, and B. Becher, "Immune attack: the role of inflammation in Alzheimer disease," *Nature Reviews. Neuroscience*, vol. 16, no. 6, pp. 358–372, 2015.
- [77] A. H. Jacobs, B. Tavitian, and the INMiND consortium, "Noninvasive molecular imaging of neuroinflammation," *Journal of Cerebral Blood Flow and Metabolism*, vol. 32, no. 7, pp. 1393–1415, 2012.
- [78] X. Fu, J. Zhang, L. Guo et al., "Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats," *Pharmacology, Biochemistry, and Behavior*, vol. 126, pp. 122–130, 2014.
- [79] C. Curtiss, J. N. Cohn, T. Vrobel, and J. A. Franciosa, "Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure," *Circulation*, vol. 58, no. 5, pp. 763–770, 1978.
- [80] A. Douillette, A. Bibeau-Poirier, S. P. Gravel et al., "The pro-inflammatory actions of angiotensin II are dependent on p65



- phosphorylation by the I $\kappa$ B kinase complex\*," *The Journal of Biological Chemistry*, vol. 281, no. 19, pp. 13275–13284, 2006.
- [81] T. Borchert, A. Hess, M. Lukačević, T. L. Ross, F. M. Bengel, and J. T. Thackeray, "Angiotensin-converting enzyme inhibitor treatment early after myocardial infarction attenuates acute cardiac and neuroinflammation without effect on chronic neuroinflammation," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 47, no. 7, pp. 1757–1768, 2020.
- [82] D. Morin, J. Musman, S. Pons, A. Berdeaux, and B. Ghaleh, "Mitochondrial translocator protein (TSPO): from physiology to cardioprotection," *Biochemical Pharmacology*, vol. 105, pp. 1–13, 2016.
- [83] J. C. Anthony, J. C. S. Breitner, P. P. Zandi et al., "Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists," *Neurology*, vol. 54, no. 11, pp. 2066–2071, 2000.
- [84] K. Arai and E. H. Lo, "Astrocytes protect oligodendrocyte precursor cells via MEK/ERK and PI3K/Akt signaling," *Journal of Neuroscience Research*, vol. 88, no. 4, pp. 758–763, 2010.
- [85] A. Armulik, G. Genové, M. Mäe et al., "Pericytes regulate the blood-brain barrier," *Nature*, vol. 468, no. 7323, pp. 557–561, 2010.
- [86] M. Freitas-Andrade, P. Carmeliet, C. Charlebois, D. B. Stanimirovic, and M. J. Moreno, "PlGF knockout delays brain vessel growth and maturation upon systemic hypoxic challenge," *Journal of Cerebral Blood Flow and Metabolism*, vol. 32, no. 4, pp. 663–675, 2012.
- [87] G. Wallays, D. Nuyens, R. Silasi-Mansat et al., "Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 12, pp. 2881–2888, 2011.
- [88] G. Daniele, S. DiLucia, P. G. Masci, and F. del Monte, "Heart and brain: complex relationships for left ventricular dysfunction," *Current Cardiology Reports*, vol. 22, no. 8, p. 72, 2020.
- [89] K. P. Doyle, R. P. Simon, and M. P. Stenzel-Poore, "Mechanisms of ischemic brain damage," *Neuropharmacology*, vol. 55, no. 3, pp. 310–318, 2008.
- [90] R. D. Bell, E. A. Winkler, I. Singh et al., "Apolipoprotein E controls cerebrovascular integrity via cyclophilin A," *Nature*, vol. 485, no. 7399, pp. 512–516, 2012.
- [91] A. Nanou, M. Bourbouli, S. Vetrano, U. Schaeper, S. Ley, and G. Kollias, "Endothelial Tpl2 regulates vascular barrier function via JNK-mediated degradation of claudin-5 promoting neuroinflammation or tumor metastasis," *Cell Reports*, vol. 35, no. 8, p. 109168, 2021.
- [92] B. V. Zlokovic, "The blood-brain barrier in health and chronic neurodegenerative disorders," *Neuron*, vol. 57, no. 2, pp. 178–201, 2008.
- [93] J. H. Seo, N. Miyamoto, K. Hayakawa et al., "Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury," *The Journal of Clinical Investigation*, vol. 123, no. 2, pp. 782–786, 2013.
- [94] W. Duan, L. Gui, Z. Zhou et al., "Adenosine A<sub>2A</sub> receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice," *Journal of the Neurological Sciences*, vol. 285, no. 1-2, pp. 39–45, 2009.
- [95] T. Uchida, M. Mori, A. Uzawa et al., "Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption," *Multiple Sclerosis*, vol. 23, no. 8, pp. 1072–1084, 2017.
- [96] Y. Yang, M. Zhang, X. Kang et al., "Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice," *Behavioral and Brain Functions*, vol. 11, no. 1, p. 30, 2015.
- [97] S. A. Villeda, J. Luo, K. I. Mosher et al., "The ageing systemic milieu negatively regulates neurogenesis and cognitive function," *Nature*, vol. 477, no. 7362, pp. 90–94, 2011.
- [98] F. Vancheri, G. Longo, S. Vancheri, and M. Henein, "Coronary Microvascular Dysfunction," *Journal of Clinical Medicine*, vol. 9, no. 9, p. 2880, 2020.
- [99] S. Hashimoto, M. Inaji, T. Nariai et al., "Usefulness of [<sup>11</sup>C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma," *Neurologia Medico-Chirurgica (Tokyo)*, vol. 59, no. 5, pp. 176–183, 2019.
- [100] J. T. Thackeray, J. P. Bankstahl, Y. Wang, K. C. Wollert, and F. M. Bengel, "Targeting amino acid metabolism for molecular imaging of inflammation early after myocardial infarction," *Theranostics*, vol. 6, no. 11, pp. 1768–1779, 2016.
- [101] S. Rivest, "Regulation of innate immune responses in the brain," *Nature Reviews. Immunology*, vol. 9, no. 6, pp. 429–439, 2009.
- [102] A. Cagnin, D. J. Brooks, A. M. Kennedy et al., "In-vivo measurement of activated microglia in dementia," *Lancet*, vol. 358, no. 9280, pp. 461–467, 2001.
- [103] J. A. Smith, A. Das, S. K. Ray, and N. L. Banik, "Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases," *Brain Research Bulletin*, vol. 87, no. 1, pp. 10–20, 2012.
- [104] J. Miyanohara, M. Kakae, K. Nagayasu et al., "TRPM2 channel aggravates CNS inflammation and cognitive impairment via activation of microglia in chronic cerebral hypoperfusion," *The Journal of Neuroscience*, vol. 38, no. 14, pp. 3520–3533, 2018.
- [105] L. Peferoen, M. Kipp, P. van der Valk, J. M. van Noort, and S. Amor, "Oligodendrocyte-microglia cross-talk in the central nervous system," *Immunology*, vol. 141, no. 3, pp. 302–313, 2014.
- [106] J. J. Volpe, H. C. Kinney, F. E. Jensen, and P. A. Rosenberg, "The developing oligodendrocyte: key cellular target in brain injury in the premature infant," *International Journal of Developmental Neuroscience*, vol. 29, no. 4, pp. 423–440, 2011.
- [107] A. L. Perraud, A. Fleig, C. A. Dunn et al., "ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology," *Nature*, vol. 411, no. 6837, pp. 595–599, 2001.
- [108] S. Kaneko, S. Kawakami, Y. Hara et al., "A critical role of TRPM2 in neuronal cell death by hydrogen peroxide," *Journal of Pharmacological Sciences*, vol. 101, no. 1, pp. 66–76, 2006.
- [109] S. Yamamoto, S. Shimizu, S. Kiyonaka et al., "TRPM2-mediated Ca<sup>2+</sup> influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration," *Nature Medicine*, vol. 14, no. 7, pp. 738–747, 2008.
- [110] Y. Hara, M. Wakamori, M. Ishii et al., "LTRPC2 Ca<sup>2+</sup>-permeable channel activated by changes in redox status confers

- susceptibility to cell death,” *Molecular Cell*, vol. 9, no. 1, pp. 163–173, 2002.
- [111] Y. Zhou, J. Zhang, L. Wang et al., “Interleukin-1 $\beta$  impedes oligodendrocyte progenitor cell recruitment and white matter repair following chronic cerebral hypoperfusion,” *Brain, Behavior, and Immunity*, vol. 60, pp. 93–105, 2017.
- [112] Y. Liu, X. M. Wu, Q. Q. Luo et al., “CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 35, no. 10, pp. 1623–1631, 2015.
- [113] W. H. Yang, S. C. Liu, C. H. Tsai et al., “Leptin induces IL-6 expression through OBRI receptor signaling pathway in human synovial fibroblasts,” *PLoS One*, vol. 8, no. 9, article e75551, 2013.
- [114] Y. du, Y. Song, X. Zhang et al., “Leptin receptor deficiency protects mice against chronic cerebral hypoperfusion-induced neuroinflammation and white matter lesions,” *Mediators of Inflammation*, vol. 2020, Article ID 7974537, 11 pages, 2020.
- [115] Y. Chen, Y. Tian, H. Tian et al., “Tamoxifen promotes white matter recovery and cognitive functions in male mice after chronic hypoperfusion,” *Neurochemistry International*, vol. 131, p. 104566, 2019.
- [116] G. Aliev, M. A. Smith, J. C. de la Torre, and G. Perry, “Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer’s disease,” *Mitochondrion*, vol. 4, no. 5-6, pp. 649–663, 2004.
- [117] J. J. Iliff, M. Wang, Y. Liao et al., “A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid  $\beta$ ,” *Science Translational Medicine*, vol. 4, no. 147, article 147ra111, 2012.
- [118] J. M. Tarasoff-Conway, R. O. Carare, R. S. Osorio et al., “Clearance systems in the brain—implications for Alzheimer disease,” *Nature Reviews. Neurology*, vol. 11, no. 8, pp. 457–470, 2015.
- [119] A. Liesz, “The vascular side of Alzheimer’s disease,” *Science*, vol. 365, no. 6450, pp. 223–224, 2019.
- [120] M. Bordeleau, A. ElAli, and S. Rivest, “Severe chronic cerebral hypoperfusion induces microglial dysfunction leading to memory loss in APPswe/PS1 mice,” *Oncotarget*, vol. 7, no. 11, pp. 11864–11880, 2016.
- [121] G. R. Frost and Y. M. Li, “The role of astrocytes in amyloid production and Alzheimer’s disease,” *Open Biology*, vol. 7, no. 12, 2017.
- [122] E. Rodriguez-Vieitez, L. Saint-Aubert, S. F. Carter et al., “Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease,” *Brain*, vol. 139, no. 3, pp. 922–936, 2016.
- [123] Y. Matsuoka, M. Picciano, J. la Francois, and K. Duff, “Fibrillar  $\beta$ -amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease,” *Neuroscience*, vol. 104, no. 3, pp. 609–613, 2001.
- [124] S. M. de la Monte and J. R. Wands, “Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 9, no. 2, pp. 167–181, 2006.
- [125] J. Wang, B. J. Gu, C. L. Masters, and Y. J. Wang, “A systemic view of Alzheimer disease – insights from amyloid- $\beta$  metabolism beyond the brain,” *Nature Reviews. Neurology*, vol. 13, no. 10, pp. 612–623, 2017.
- [126] P. Venkat, J. Chen, and M. Chopp, “Exosome-mediated amplification of endogenous brain repair mechanisms and brain and systemic organ interaction in modulating neurological outcome after stroke,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 38, no. 12, pp. 2165–2178, 2018.
- [127] C. Frühbeis, D. Fröhlich, W. P. Kuo, and E. M. Krämer-Albers, “Extracellular vesicles as mediators of neuron-glia communication,” *Frontiers in Cellular Neuroscience*, vol. 7, 2013.
- [128] D. Fröhlich, W. P. Kuo, C. Frühbeis et al., “Multifaceted effects of oligodendroglial exosomes on neurons: impact on neuronal firing rate, signal transduction and gene regulation,” *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*, vol. 369, no. 1652, article 20130510, 2014.
- [129] L. L. Sun, M. J. Duan, J. C. Ma et al., “Myocardial infarction-induced hippocampal microtubule damage by cardiac originating microRNA-1 in mice,” *Journal of Molecular and Cellular Cardiology*, vol. 120, pp. 12–27, 2018.
- [130] S. Acharya, A. Salgado-Somoza, F. M. Stefanizzi et al., “Non-coding RNAs in the brain-heart axis: the case of Parkinson’s disease,” *International Journal of Molecular Sciences*, vol. 21, no. 18, 2020.
- [131] J. A. Cannon, L. Shen, P. S. Jhund et al., “Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction,” *European Journal of Heart Failure*, vol. 19, no. 1, pp. 129–137, 2017.